Drug Profile
Research programme: astrocytic target-based therapeutics - GliaCure
Latest Information Update: 28 Sep 2018
Price :
$50
*
At a glance
- Originator GliaCure
- Class
- Mechanism of Action Glial cell modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Depressive disorders; Sleep disorders
Most Recent Events
- 28 Sep 2018 No recent reports of development identified for research development in Depressive disorders in USA
- 28 Sep 2018 No recent reports of development identified for research development in Sleep-disorders in USA
- 14 Sep 2014 Research programme: glial-targeted therapeutics - GliaCure is available for licensing as of 14 Sep 2014. http://gliacure.com/